论坛 › 云南 › 新医疗保险价即将颁布，这4款肺癌药首次进医疗保险（附药物购买点和适应症查询指南）！

l14107cb 发表于 2024-6-23 23:36:46

新医疗保险价即将颁布，这4款肺癌药首次进医疗保险（附药物购买点和适应症查询指南）！

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_gif/Uia9ysy1SpiaHQTC9kxPGDVHK5VehPPlaKxmKbHdaAkicFrlHWEZfv9SXDxfSq1iaZicaeWPwk89aZBA04lg4xrH7EA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023年12月13日，国家医疗<span style="color: black;">保证</span>局正式<span style="color: black;">颁布</span>了</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">《国家基本医疗保险、工伤保险和生育保险<span style="color: black;">药物</span>目录（2023年）》</span></strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">随着</span><span style="color: black;">新<span style="color: black;">医疗保险</span>目</span><span style="color: black;">录的</span><span style="color: black;">正式落地，<span style="color: black;">这次</span>共有126个新药新增进入目录，平均降价</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">61.7%</span></strong></span><span style="color: black;">，预计<span style="color: black;">将来</span>两年将为<span style="color: black;">病人</span>减负超</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">400亿元</span></strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">更值得庆祝的是，<span style="color: black;">这次</span>目录新增了4款肺癌药。<span style="color: black;">另外</span>，<span style="color: black;">亦</span>有3款肺癌药新增了适应症！</span><span style="color: black;">新的<span style="color: black;">医疗保险</span>目录将自2024年1月1日起正式执行，届时<span style="color: black;">亦</span>将<span style="color: black;">颁布</span>新的<span style="color: black;">医疗保险</span>价（文末附有<span style="color: black;">药物</span>购买点<span style="color: black;">查找</span>指南和<span style="color: black;">药物</span>适应症<span style="color: black;">查找</span>指南）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">01</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">新增<span style="color: black;">药品</span>：</strong></span><strong style="color: blue;">甲磺酸贝福替尼胶囊</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限既往经表皮生长因子受体（EGFR）酪氨酸激酶<span style="color: black;">控制</span>剂（TKI）治疗时或治疗后<span style="color: black;">显现</span><span style="color: black;">疾患</span><span style="color: black;">发展</span>，并且经检测确认存在</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">EGFR T790M突变阳性</span></strong></span><span style="color: black;">的局部晚期或转移性非小细胞肺癌（NSCLC）成人<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、非<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">6000元/盒（25 mg*40粒）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2024年1月1日-2025年12月31日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在贝福替尼上市前，已有三款EGFR-TKI在<strong style="color: blue;"><span style="color: black;">国内<span style="color: black;">获准</span>上市并加入<span style="color: black;">医疗保险</span>目录</span></strong>——</span><strong style="color: blue;"><span style="color: black;">奥希替尼、阿美替尼、伏美替尼</span></strong><span style="color: black;">，<span style="color: black;">获准</span>用于治疗EGFR-TKI耐药后T790M阳性突变非小细胞肺癌。如今，这些<span style="color: black;">病人</span>又迎来了一位强大的盟友——贝福替尼！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">甲磺酸贝福替尼是一款中国原研的第三代EGFR-TKI</span></strong><span style="color: black;">，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">于2023年5月31日<span style="color: black;">获准</span>上市，同年12月便纳入了<span style="color: black;">医疗保险</span>目录</span></strong></span><span style="color: black;">。从上市到纳入<span style="color: black;">医疗保险</span>仅半年的时间，充分说明了贝福替尼在满足<span style="color: black;">病人</span>临床需求方面有<span style="color: black;">极重</span>的<span style="color: black;">潜能</span>！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">贝福替尼的III期<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，<span style="color: black;">针对</span>既往未经治疗的EGFR<span style="color: black;">敏锐</span>突变局部晚期或转移性NSCLC<span style="color: black;">病人</span></span><span style="color: black;">，贝福替尼组由独立审查委员会<span style="color: black;">评定</span>的</span><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为22.1个月</span></strong><span style="color: black;">，埃克替尼组为13.8个月（P&lt;0.0001）</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">安全性<span style="color: black;">科研</span>结果<span style="color: black;">显示</span>，贝福替尼在安全性上与既往<span style="color: black;">报告</span>的<span style="color: black;">关联</span>结果一致。尽管大部分<span style="color: black;">病人</span>均会<span style="color: black;">出现</span>与治疗<span style="color: black;">关联</span>的不良事件，但</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">大<span style="color: black;">都数</span>不良事件均为轻中度</span></strong></span><span style="color: black;">。最<span style="color: black;">平常</span>的与治疗<span style="color: black;">关联</span>的不良事件为血小板减少症、头痛、丙氨酸氨基转移酶（ALT）<span style="color: black;">上升</span>等，可耐受可控。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">02</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">新增<span style="color: black;">药品</span>：恩曲替尼胶囊</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">1、12岁及以上，经充分验证的检测<span style="color: black;">办法</span>诊断为携带<strong style="color: blue;"><span style="color: black;">神经营养酪氨酸受体激酶（NTRK）融合基因</span></strong>且不<span style="color: black;">包含</span>已知<span style="color: black;">得到</span>性耐药突变的实体瘤：<span style="color: black;">身患</span>局部晚期、转移性<span style="color: black;">疾患</span>或手术切除可能<span style="color: black;">引起</span>严重并发症的<span style="color: black;">病人</span>，或<span style="color: black;">没</span>满意替代治疗或既往治疗失败的<span style="color: black;">病人</span>；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2、</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">ROS1阳性</span></strong></span><span style="color: black;">的局部晚期或转移性非小细胞肺癌（NSCLC）成人<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、非<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">27000元/盒（200 mg*90粒）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2024年1月1日-2025年12</span><span style="color: black;">月31日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">恩曲替尼是一款TRK、ROS1和ALK<span style="color: black;">控制</span>剂</strong></span><span style="color: black;">，对携带NTRK、ROS1或ALK融合基因的晚期或转移性肿瘤<span style="color: black;">病人</span><span style="color: black;">拥有</span>快速、持久的疗效，<strong style="color: blue;"><span style="color: black;"><span style="color: black;">能够</span><span style="color: black;">经过</span>血脑屏障</span></strong></span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">临床<span style="color: black;">科研</span><span style="color: black;">表示</span></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">总体有效率为57.4%</span></strong></span><span style="color: black;">，其中肺癌<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">总体有效率（ORR）为70%</span></strong></span><span style="color: black;">，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（PFS）<span style="color: black;">更加是</span>长达14.9个月</span></strong></span><span style="color: black;">！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">针对</span>NTRK融合基因，截止至<span style="color: black;">日前</span>，国内已有两款针对性的<span style="color: black;">药品</span><span style="color: black;">获准</span>上市，分别是<strong style="color: blue;"><span style="color: black;">拉罗替尼</span></strong></span><span style="color: black;"><strong style="color: blue;">（未进<span style="color: black;">医疗保险</span>）</strong></span><span style="color: black;">和<strong style="color: blue;"><span style="color: black;">恩曲替尼</span></strong></span><span style="color: black;"><strong style="color: blue;">（已进<span style="color: black;">医疗保险</span>）</strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">而<span style="color: black;">针对</span>ROS1融合阳性，国内已有两款<span style="color: black;">药品</span><span style="color: black;">获准</span>上市，分别是</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">克唑替尼</span></strong></span><span style="color: black;"><strong style="color: blue;">（已进<span style="color: black;">医疗保险</span>）</strong></span><span style="color: black;">和</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">恩曲替尼</span></strong></span><span style="color: black;"><strong style="color: blue;">（已进<span style="color: black;">医疗保险</span>）</strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在刚结束的2023年世界肺癌大会（WCLC）上，恩曲替尼的最新数据<span style="color: black;">表示</span>，</span><span style="color: black;">恩曲替尼治疗ROS1阳性非小细胞肺癌<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（mPFS）高达39.4个月</span></strong></span><span style="color: black;">，克唑替尼仅为15.9个月</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">；<span style="color: black;">另外</span>，恩曲替尼可进一步降低了</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">33.8%的死亡<span style="color: black;">危害</span></span></strong></span><span style="color: black;">，为<span style="color: black;">更加多</span>ROS1阳性非小细胞肺癌<span style="color: black;">病人</span>迎来了长<span style="color: black;">存活</span>生机。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">03</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">新增<span style="color: black;">药品</span>：</strong></span><strong style="color: blue;">谷美替尼片</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限<span style="color: black;">拥有</span></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">间质-上皮转化因子（MET）外显子14跳变</span></strong></span><span style="color: black;">的局部晚期或转移性非小细胞肺癌。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、非<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3990元/盒（50 mg*24片）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">202</span><span style="color: black;">4年1月1日-2025年12月3</span><span style="color: black;">1日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">截止至<span style="color: black;">日前</span>，国内已有三款针对MET外显子14跳跃突变的靶向药<span style="color: black;">获准</span>上市，分别是</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">赛沃替尼</span></strong></span><strong style="color: blue;"><span style="color: black;">（已进<span style="color: black;">医疗保险</span>）</span></strong><span style="color: black;">、</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">谷美替尼</span></strong></span><strong style="color: blue;"><span style="color: black;">（已进<span style="color: black;">医疗保险</span>）</span></strong><span style="color: black;">和</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">伯瑞替尼</span></strong></span><strong style="color: blue;"><span style="color: black;">（未进<span style="color: black;">医疗保险</span>）</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">GLORY<span style="color: black;">科研</span>结果显</span><span style="color: black;">示，谷美替尼治疗后，MET 14号外显子跳跃突变非小细胞肺癌<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">总体客观缓解率（ORR）达到了为66%</span></strong></span><span style="color: black;">；</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位缓解<span style="color: black;">连续</span>时间（mDoR）总体人群8.3个月</span></strong></span><span style="color: black;">；</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（mPFS）总体人群8.5个月</span></strong></span><span style="color: black;">；</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位总<span style="color: black;">存活</span>期（mOS）总体人群17.3个月</span></strong></span><span style="color: black;">。<span style="color: black;">另外</span>，5例脑转移的<span style="color: black;">病人</span><span style="color: black;">亦</span>观察到颅内肿瘤缓解</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">04</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">新增<span style="color: black;">药品</span>：</strong></span><strong style="color: blue;">伊鲁阿克片</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限既往接受过克唑替尼治疗后<span style="color: black;">疾患</span><span style="color: black;">发展</span>或对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、非<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">8258.15元/盒（60 mg*30片）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">23800元/盒（60 mg*90片）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">202</span><span style="color: black;">4年1月1日-2025年12月3</span><span style="color: black;">1日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">截止至<span style="color: black;">日前</span>，共7种ALK<span style="color: black;">控制</span>剂在国内<span style="color: black;">获准</span>且</span><span style="color: black;">均已纳入<span style="color: black;">医疗保险</span>目录</span><span style="color: black;">：</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">一代：</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">克唑替尼</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">二代：</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">塞瑞替尼、阿来替尼、恩沙替尼、布格替尼、伊鲁阿克</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">三代：</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">洛拉替尼（又名劳拉替尼）</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">伊鲁阿克<span style="color: black;">做为</span>新一款二代ALK<span style="color: black;">控制</span>剂，可<span style="color: black;">控制</span>不同融合类型的野生型以及ALK<span style="color: black;">控制</span>剂耐药突变的ALK激酶活性，<span style="color: black;">同期</span>可有效<span style="color: black;">控制</span>不同融合类型ROS1激酶的活性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">INTELLECT<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，伊鲁阿克治疗克唑替尼耐药的ALK阳性非小细胞肺癌<span style="color: black;">病人</span>后，<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">客观缓解率（ORR）为69.9%</span></strong></span><span style="color: black;">，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（mPFS）为19.81个月</span></strong></span><span style="color: black;">，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">1年总<span style="color: black;">存活</span>率（OS）为85.2%</span></strong></span><span style="color: black;">，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">2年总<span style="color: black;">存活</span>率（OS）为57.9%</span></strong></span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">安全性数据<span style="color: black;">表示</span>，伊鲁阿克治疗后的严重不良反应<span style="color: black;">出现</span>率仅为6.8%；<span style="color: black;">另外</span>，伊鲁阿克治疗后<span style="color: black;">引起</span>停药的严重不良反应<span style="color: black;">出现</span>率仅为2.7%，这些数<span style="color: black;">据述</span>明伊鲁阿克的总体安全性较好。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">以上4种肺癌新增<span style="color: black;">药品</span>均为靶向药，接下来科普君就为<span style="color: black;">大众</span>介绍3款新增适应症的<span style="color: black;">药品</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">01</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新增肺癌适应症：</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">信迪利单抗注射液</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限：1、<span style="color: black;">最少</span>经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤的治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2、</span><span style="color: black;">非鳞状非小细胞肺癌：</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">(1)表皮生长因</span><span style="color: black;">子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性、不可手术切</span><span style="color: black;">除的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">(2)表皮生长因子受体酪氨酸激酶<span style="color: black;">控制</span>剂(EGFR-TKI)治疗失败的EGFR 基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)<span style="color: black;">病人</span>的治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3、不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(NSCLC)的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">4、既往未接受过系统治疗的不可切除或转移性肝细胞癌的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">5、不可切除的局部晚期、复发或转移性食管鳞癌的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">6、不可切除的局部晚期、复发或转移性胃及胃食管交界处腺癌的一线治疗。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、2022年<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">1080元/瓶（10 ml/100 mg）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">202</span><span style="color: black;">4年1月1日-2025年12月3</span><span style="color: black;">1日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023年5月19日，国家食品<span style="color: black;">药物</span>监督管理局（NMPA）正式<span style="color: black;">准许</span>了，PD-1单抗信迪利单抗用于“经表皮生长因子受体（EGFR）酪氨酸激酶<span style="color: black;">控制</span>剂（TKI）治疗失败的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）”的适应症申请</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">这是信迪利单抗在中国<span style="color: black;">获准</span>的第7项适应症了。同年的12月，该适应症<span style="color: black;">亦</span>正式纳入了国家<span style="color: black;">医疗保险</span>目录！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">ORIENT-31是信迪利单抗的一项<span style="color: black;">重要</span>III期临床<span style="color: black;">科研</span>，首次证实了PD-1<span style="color: black;">控制</span>剂±贝伐珠单抗联合化疗能够<span style="color: black;">明显</span>延长EGFR-TKI治疗失败的EGFR基因突变非鳞状非小细胞肺癌人群<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（PFS）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，与单纯化疗相比，信迪利单抗+化疗<span style="color: black;">明显</span>改善了<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（5.5个月 vs. 4.3个月）</span></strong></span><span style="color: black;">；与单纯化疗相比，信迪利单抗+贝伐珠单抗+化疗<span style="color: black;">明显</span>延长了<span style="color: black;">病人</span>的改善的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（7.2个月 vs. 4.3个月)</span></strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">不仅如此，信迪利单抗<span style="color: black;">亦</span>使得<span style="color: black;">病人</span>的总<span style="color: black;">存活</span>期<span style="color: black;">明显</span>延长。信迪利单抗+贝伐珠单抗+化疗组</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位总<span style="color: black;">存活</span>期为21.1个月</span></strong></span><span style="color: black;">，信迪利单抗+化疗组为</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">20.5个月</span></strong></span><span style="color: black;">，单纯化疗组为19.2个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">而安全性数据<span style="color: black;">亦</span>与既往<span style="color: black;">报告</span>的信迪利单抗、贝伐珠单抗<span style="color: black;">关联</span>临床<span style="color: black;">科研</span>结果一致，未见新发安全性信号。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">总而言之，信迪利单抗<span style="color: black;">做为</span><span style="color: black;">全世界</span>首个<span style="color: black;">获准</span>用于经EGFR-TKI治疗失败的EGFR阳性非鳞状非小细胞肺癌的PD-1<span style="color: black;">控制</span>剂，成功实现了EGFR阳性非鳞状非小细胞肺癌在免疫治疗的“零突破”，源源<span style="color: black;">持续</span>地为<span style="color: black;">病人</span>带来疗效、安全性以及价格上的好<span style="color: black;">信息</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">02</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新增肺癌适应症：</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">特瑞普利单抗注射液</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限：1、既往接受全身系统治疗失败的不可切除或转移性黑色素瘤的治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2、含铂化疗失败<span style="color: black;">包含</span>新辅助或辅助化疗12个月内<span style="color: black;">发展</span>的局部晚期或转移性尿路上皮癌的治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3、既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌<span style="color: black;">病人</span>的治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">4、局部复发或转移性鼻咽癌<span style="color: black;">病人</span>的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">5、不可切除局部晚期/复发或转移性食管鳞癌的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">6、表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性、不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)的一线治疗。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、2022年<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">825元/瓶（80 mg）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">202</span><span style="color: black;">4年1月1日-2025年12月3</span><span style="color: black;">1日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">肺癌适应症是特瑞普利单抗在中国<span style="color: black;">获准</span>的第六项适应症。这将为中国的晚期非鳞状非小细胞肺癌<span style="color: black;">病人</span>带来<span style="color: black;">更加多</span>治疗<span style="color: black;">选取</span>！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">CHOICE-01<span style="color: black;">科研</span>是特瑞普利单抗的一项<span style="color: black;">重要</span>III期<span style="color: black;">科研</span>，旨在<span style="color: black;">评定</span>其联合化疗一线治疗非小细胞肺癌（NSCLC）的疗效及安全性</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，特瑞普利单抗联合化疗一线治疗<span style="color: black;">没</span>EGFR/ALK突变的晚期NSCLC<span style="color: black;">病人</span>，<span style="color: black;">明显</span>延长</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（PFS）至8.4个月</span></strong></span><span style="color: black;">，单纯化疗为5.6个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">另外</span>，该联合<span style="color: black;">方法</span>还<span style="color: black;">能够</span>将<span style="color: black;">病人</span>的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">疾患</span><span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span>降低了51%</span></strong></span><span style="color: black;">。安全性数据<span style="color: black;">表示</span>，特瑞普利单抗联合化疗治疗<span style="color: black;">时期</span>，未观察到新的安全性信号，且治疗<span style="color: black;">时期</span>≥3级不良事件（AE）<span style="color: black;">出现</span>率与单纯化疗<span style="color: black;">方法</span><span style="color: black;">类似</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">特瑞普利单抗，这款中国原研的高质量免疫<span style="color: black;">药品</span>，已<span style="color: black;">获准</span>肺癌适应症并2023年12月13日成功纳入<span style="color: black;">医疗保险</span>。这<span style="color: black;">寓意</span>着，我国的肺癌<span style="color: black;">病人</span>将迎来<span style="color: black;">更加多</span>经济实惠的治疗<span style="color: black;">选取</span>，迈向长生存之路的坚实一步！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">03</span></strong></span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新增肺癌术后辅助适应症：</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">甲磺酸奥希替尼片</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">1、适应症</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">限：1、</span><span style="color: black;">IB-IIIA期存在表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的非小细胞肺癌</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">(NSCLC)<span style="color: black;">病人</span>的治疗，<span style="color: black;">病人</span>须既往接受过手术切除治疗，并由<span style="color: black;">大夫</span>决定接受或不接受辅助化疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2、<span style="color: black;">拥有</span>表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人<span style="color: black;">病人</span>的一线治疗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3、既往经EGFR酪氨酸激酶<span style="color: black;">控制</span>剂(TKI)治疗时或治疗后<span style="color: black;">显现</span><span style="color: black;">疾患</span><span style="color: black;">发展</span>，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性NSCLC成人<span style="color: black;">病人</span>的治疗。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">2、<span style="color: black;">医疗保险</span>标准<span style="color: black;">归类</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">乙类</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">3、2022年<span style="color: black;">医疗保险</span>价（仅供参考）</strong></span></p>25 mg*40粒<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">5580元/盒（80&nbsp;mg*30片）</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">4、协议有效期</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">202</span><span style="color: black;">4年1月1日-2024年12月3</span><span style="color: black;">1日</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">奥希替尼<span style="color: black;">做为</span>在我国首款<span style="color: black;">获准</span>的三代EGFR-TKI，在肺癌晚期治疗有了重大突破。如今，奥希替尼“前移”来到了围手术<span style="color: black;">周期</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">截止至<span style="color: black;">日前</span>，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">奥希替尼是<span style="color: black;">独一</span>一款在<span style="color: black;">医疗保险</span>目录内可进行术后辅助治疗的三代EGFR-TKI靶向药</span></strong></span><span style="color: black;">；<span style="color: black;">另外</span>，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">奥希替尼<span style="color: black;">亦</span>是<span style="color: black;">独一</span>一款的晚期一</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">线</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">、二线以及辅助治疗适应证均纳入<span style="color: black;">医疗保险</span>的三代EGFR-TKI靶向药</span></strong></span><span style="color: black;">，可谓是“实至名归”。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">ADAURA<span style="color: black;">科研</span>是奥希替尼的<span style="color: black;">重要</span>III期临床<span style="color: black;">科研</span>，旨在<span style="color: black;">评定</span>奥希替尼术后辅助治疗EGFR突变阳性的IB-IIIA期非小细胞肺癌<span style="color: black;">病人</span>疗效和安全性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2020年美国临床肿瘤学会（ASCO）大会上首次<span style="color: black;">报告</span>了ADAURA<span style="color: black;">科研</span>。结果<span style="color: black;">表示</span>，奥希替尼治疗后，IB-IIIA期非小细胞肺癌<span style="color: black;">病人</span>的<span style="color: black;">没</span>病<span style="color: black;">存活</span>期（DFS）获益<span style="color: black;">明显</span>，并且远处复发率<span style="color: black;">明显</span>降低</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2022年欧洲肿瘤内科学会（ESMO）大会更新了4年随访的DFS数据。结果<span style="color: black;">表示</span>，<span style="color: black;">针对</span>IB-IIIA期<span style="color: black;">病人</span>而言，奥希替尼组</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位<span style="color: black;">没</span>病<span style="color: black;">存活</span>期（DFS）达到了65.8个月</span></strong></span><span style="color: black;">，<span style="color: black;">明显</span>长于安慰剂组（仅为28.1个月）；<span style="color: black;">另外</span>，奥希替尼<span style="color: black;">亦</span>可<span style="color: black;">明显</span></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">降低<span style="color: black;">病人</span>CNS复发<span style="color: black;">危害</span></span></strong></span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023年美国临床肿瘤学会（ASCO）大会最新<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，<span style="color: black;">针对</span>IB-IIIA期<span style="color: black;">病人</span>而言，奥希替尼组的5年<span style="color: black;">存活</span>率（OS）<span style="color: black;">明显</span>高于安慰剂组</span><span style="color: black;"><span style="color: black;"></span></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">奥希替尼的术后辅助适应症纳入<span style="color: black;">医疗保险</span>，对肺癌<span style="color: black;">病人</span><span style="color: black;">来讲</span><span style="color: black;">没</span>疑是一个重大的突破，大大减轻了术后接受辅助治疗<span style="color: black;">病人</span>的经济<span style="color: black;">包袱</span>！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">你心目中的那款抗癌神药进<span style="color: black;">医疗保险</span>了吗？<span style="color: black;">能够</span><span style="color: black;">按照</span>以下操作指南，关注“</span><span style="color: black;"><strong style="color: blue;">国家<span style="color: black;">医疗保险</span>局</strong></span><span style="color: black;">”公众号<span style="color: black;">查找</span>哦~</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">爱好</span>这篇<span style="color: black;">文案</span>的话，记得</span><span style="color: black;"><span style="color: black;"><strong style="color: blue;">点赞、分享</strong></span></span><span style="color: black;">出去哦~</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">点击下方关注，<span style="color: black;">认识</span><span style="color: black;">更加多</span>抗癌知识</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">

j8typz 发表于 2024-10-22 12:15:43

期待楼主的下一次分享！”

m5k1umn 发表于 2024-10-24 05:38:25

你的留言真是温暖如春，让我感受到了无尽的支持与鼓励。

查看完整版本: 新医疗保险价即将颁布，这4款肺癌药首次进医疗保险（附药物购买点和适应症查询指南）！